BMJ. The truth about Tamiflu? Data access is matter of trust.

[Giuseppe]

The truth about Tamiflu? Data access is matter of trust. (BMJ, edited)

2. BMJ. 2010 Jan 13;340:c134. doi: 10.1136/bmj.c134.

The truth about Tamiflu? Data access is matter of trust.

Maryon-Davis AR.

PMID: 20071427 [PubMed - indexed for MEDLINE]

* Letter

MeSH Terms:

* Access to Information*
* Antiviral Agents/therapeutic use*
* Humans
* Influenza A Virus, H1N1 Subtype*
* Influenza, Human/drug therapy*
* Oseltamivir/therapeutic use*

Substances:

* Antiviral Agents
* Oseltamivir

-
------

[Sally Furniss]

Re: BMJ. The truth about Tamiflu? Data access is matter of trust.

Letters

The truth about Tamiflu?

Data access is matter of trust

The UK Faculty of Public Health strongly supports the BMJ?scall for mandatory disclosure of raw data of all trials citedin drug licensing applications and marketing claims.¹
We see this as a first step towards a position in which onlyexternal independent trials published in peer reviewed journals,with full access to raw data, should be allowable when seekinga licence or marketing a product. This would require internationalagreement by health technology regulators.
Interpreting the evidence base for healthcare planning and commissioningis a key public health function. Full disclosure and opennessto scrutiny of evidence on efficacy and safety are crucial ifthe pharmaceutical industry is to maintain the full trust andconfidence of patients, practitioners, policy makers, and thewider public.

http://www.bmj.com/cgi/content/full/340/jan13_3/c134